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Objectives. The purpose of this study was to evaluate the safety,
feasibility, optimal deployment technique and 1-year clinical
outcome for the Advanced Cardiovascular Systems (ACS) Mul-
tiLink stent.
Background. Optimal stent deployment assessed by quantita-
tive coronary angiography and intravascular ultrasound (IVUS) is
associated with improved clinical outcome.
Methods. Forty-nine consecutive patients with a discrete steno-
sis in a native coronary artery 3 to 4 mm in diameter were treated
with the new, balloon-expandable ACS MultiLink stent. Stent
expansion was assessed in all patients using quantitative coronary
angiography and serial IVUS imaging after 8-, 12- and 16-atm
inflations. Clinical follow-up was obtained at 30 days and 1 year.
Results. All 49 patients had successful placement of a Mul-
tiLink stent without death, emergency coronary artery bypass
graft surgery or Q wave myocardial infarction. After placement of
the MultiLink stent, the minimal lumen diameter increased from
1.24 to 2.98 mm (p < 0.001), and diameter stenosis decreased
from 61% to 7% (p 5 0.001). Minimal lumen cross-sectional area
by IVUS increased progressively after 8, 12 and 16 atm (5.6 to 6.8
to 7.4 mm2, respectively, p < 0.001). However, only 64% of stents
achieved a lumen/reference area ratio >270%. No adverse clinical
events occurred by 30 days, and by 1 year only one patient (2.0%)
required revascularization of the stented artery.
Conclusions. Treatment of stenoses in native coronary arteries
with the MultiLink stent is associated with a high success rate and
a low incidence of adverse events by 1 year, despite the fact that
the majority of stents did not meet IVUS-defined criteria for
“optimal stenting” derived from first-generation devices.
(J Am Coll Cardiol 1998;31:50–6)
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The use of coronary metallic endovascular prostheses (stents)
has risen exponentially since approval by the Food and Drug
Administration (FDA) in 1993 to 1994. It is estimated that
30% to 40% of all percutaneous coronary interventions per-
formed currently in the United States involve placement of a
stent. By virtue of their ability to seal arterial dissections,
reduce elastic recoil, maximize acute lumen diameter and
reduce the rates of subsequent angiographic restenosis and
revascularization compared with conventional balloon angio-
plasty, stents have become the technique of choice for urgent
treatment of abrupt or threatened closure, as well as an
elective treatment for suitable lesions (1,2).
The ability of these “first-generation” stents to improve
both short-term procedural and long-term outcome thus rep-
resents a major breakthrough in percutaneous coronary revas-
cularization. However, these initial devices have significant
mechanical limitations (e.g., excessive rigidity, articulation
gaps, nonuniform expansion). A number of second-generation
stents have therefore been proposed, whose geometry can
simultaneously impart both enhanced flexibility (to facilitate
delivery) and excellent radial strength once expanded (to
provide uniform scaffolding throughout the stented seg-
ment) (3). One such second-generation device is the ACS
(Advanced Cardiovascular Systems) MultiLink stent. Before
commencement of a large, multicenter, randomized trial
comparing this new stent with the approved Palmaz-Schatz
coronary stent, an open-label pilot study was performed at
three U.S. sites to evaluate the safety, feasibility and optimal
deployment technique for the MultiLink stent as assessed by
quantitative coronary angiography and serial intravascular
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ultrasound (IVUS). This report describes that initial U.S.
experience.
Methods
The ACS MultiLink stent. The MultiLink stent is con-
structed from a stainless-steel cylinder that is laser-etched into
a pattern of repeating, nonoverlapping loops connected by
interposed bridges (Fig. 1). All stents deployed in this study
were 15 mm in length and were mounted on either a 3.0-mm or
3.5-mm delivery balloon, covered by a retractable 5F sheath.
Study patients. Forty-nine consecutively treated patients
were enrolled at three centers (Beth Israel Hospital, Boston;
St. Vincent’s Hospital, Indianapolis; and the University of
Alabama at Birmingham) under an Investigational Device
Exemption from the FDA. The investigational protocol was
approved by the respective Institutional Review Boards. Each
patient had angina or objective evidence of myocardial isch-
emia, or both, as well as a single (,12 mm) primary or
previously treated lesion in a native coronary artery whose
reference diameter was between 3.0 and 3.5 mm. Patients with
a recent myocardial infarction (within 5 days) or a contraindi-
cation to aspirin or anticoagulation were excluded from the
study.
Stent procedure. Baseline angiography was performed af-
ter the administration of 150 mg of intracoronary nitroglycerin.
After predilation with a conventional angioplasty balloon, the
ACS MultiLink coronary stent was delivered to the target
lesion over a 0.014-in. (0.035-cm) exchange length guide wire.
The delivery sheath was withdrawn and appropriate stent
position was reconfirmed by angiography. The stent delivery
balloon was inflated to 8 atm for 30 s. After removal of the
delivery system and administration of 150 mg of intracoronary
nitroglycerin, angiography was repeated and IVUS imaging
was performed using a 2.9F or 3.2F UltraCross Catheter
(CardioVascular Imaging Systems). Balloon inflation was then
performed to 12 atm within the stent using a noncompliant
balloon (balloon/artery ratio 1:1.1). After repeat angiography
and IVUS, the same noncompliant balloon was inflated to
16 atm within the stent. Angiography and IVUS were then
repeated. The protocol prohibited postdilation with a balloon
whose nominal size was .3.5 mm.
Medical therapy and clinical follow-up. All patients re-
ceived 325 mg of aspirin before the procedure. All patients also
received 10 mg of warfarin on the evening before the proce-
dure, and then warfarin was titrated to an international
normalized ratio (INR) of 2 to 3 for 4 weeks. Heparin boluses
were given during the procedure to raise the activated clotting
time to .300 s. Heparin was restarted 6 h after sheath removal
(timed to an activated clotting time of 150 to 170 s) and titrated
to an activated partial thromboplastin time of 60 to 80 s until
a therapeutic INR was achieved. Clinical follow-up was ob-
tained at 30 days, 6 months and 1 year.
Quantitative coronary angiography. All cine angiograms
were forwarded to the Washington Hospital Center Angio-
graphic Core Laboratory for review by observers who had no
knowledge of the early and late clinical outcomes. Standard
qualitative morphologic criteria were used to evaluate stenosis
complexity before and after stent deployment. Using the
contrast-filled guiding catheter as the calibration source, ref-
erence and minimal lumen diameters were determined before
stent deployment, after stent deployment at 8 atm and after
16 atm using a validated algorithm. The final residual minimal
lumen diameter and percent diameter stenosis were identified
within the segment (“lesion”) as well as within the axial length
of the stent (“stent”).
Intravascular ultrasound. The IVUS catheter was deliv-
ered distal to the treated segment. Imaging was performed
during slow (1 mm/s), motorized pullback through the treated
segment and into the proximal reference vessel. Images were
recorded on high quality S-VHS videotape and analyzed at the
Center for Research in Cardiovascular Interventions under the
direction of Dr. Paul G. Yock. Lumen and vessel minimal
diameter and maximal diameter and cross-sectional area
(CSA) were measured distal and proximal to the stent, as well
as at the proximal, distal and narrowest areas within the stent.
Additional variables were calculated as follows:
Reference CSA
5 ~CSA @proximal to stent# 1 CSA @distal to stent#!/2.
Eccentricity ratio
5 Minor axis ~tightest stent!/Major axis ~tightest stent!.
Percent expansion
5 Lumen CSA ~stent!/Lumen CSA ~reference!.
Abbreviations and Acronyms
ACS 5 Advanced Cardiovascular Systems
AHA/ACC 5 American Heart Association/American
College of Cardiology
CSA 5 cross-sectional area
FDA 5 Food and Drug Administration
INR 5 international normalized ratio
IVUS 5 intravascular ultrasound
Figure 1. The ACS MultiLink Stent is shown, from top to bottom, in
its collapsed form, mounted on the delivery catheter, expanded on the
delivery balloon and after balloon expansion.
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Data analysis. All data were collected and processed at the
Cardiovascular Data Analysis Center under the direction of
Dr. Richard E. Kuntz. Statistical analyses were performed
using the SAS for Windows statistical program (version 6.10–
6.12). Data are expressed as the mean value 6 SD. Compari-
sons between groups were made using analysis of variance.
Results
Demographics. From August 1995 through May 1996, 49
patients were enrolled in the MultiLink Pilot Study. The
patients’ mean age was 59 years and 86% were men (Table 1).
Fifty-one percent of patients had a previous myocardial infarc-
tion and 65% had either Canadian Cardiovascular Society class
III or IV angina. Forty-three percent of stents were placed in
the right coronary artery, with 33% in the left anterior
descending coronary artery and 25% in the left circumflex
artery.
Procedural outcome. All 49 patients had successful place-
ment of a MultiLink stent, with no instances of procedural
death, emergency bypass surgery or Q wave myocardial infarc-
tion. Fourteen dissections (29%) occurred after predilation,
but only three dissections remained evident after stent place-
ment (6%) (Table 2). Forty-three patients received only one
MultiLink stent, but five patients received two MultiLink
stents, and one patient received three stents to cover a
dissection proximal or distal to the original stent. One patient
had a Palmaz-Schatz coronary stent placed in addition to the
MultiLink stent. There was no angiographic evidence of abrupt
closure, distal embolization or perforation in any patient. One
patient had reduced flow (Thrombolysis in Myocardial Infarc-
tion flow grade 2) after stent placement. Four patients (8.0%)
had non–Q wave myocardial infarctions (creatine kinase, MB
fraction greater than twice the normal level). Two patients
(4.0%) developed femoral hematomas, but neither required
surgical repair or transfusion.
Clinical follow-up at 30 days was available for 48 patients.
No major adverse events occurred during this period. Specif-
ically, no patient had stent thrombosis or required repeat
revascularization of the target vessel. One-year clinical
follow-up was available for 43 patients (91%). No patients
died; one patient (2.0%) required repeat angioplasty for
restenosis of the target site; and two other patients (4.6%)
underwent revascularization of other vessels.
Quantitative coronary angiography. Complete angio-
graphic data were available for 47 patients (two films were
unavailable for analysis). The majority of lesions treated were
in American Heart Association/American College of Cardiol-
ogy (AHA/ACC) class B2 or C, with a mean lesion length of
9.6 mm (Table 2). Before intervention, the mean reference
vessel diameter was 3.18 6 0.49 mm, and the minimal lumen
diameter was 1.24 6 0.46 mm, corresponding to a baseline
diameter stenosis 61 6 13% (Table 3). After placement of the
MultiLink stent, the minimal lumen diameter increased to
2.49 6 0.42 mm, corresponding to a diameter stenosis 21 6
11%. After dilation, the minimal lumen diameter within the
stent increased further to 2.98 6 0.28 mm, corresponding to a
diameter stenosis 7.0 6 9.0%.
Table 1. Baseline Demographics
Age (yr) 59 6 11
Male 42 (86%)
Female 7 (14%)
Hypertension 27 (55%)
Diabetes mellitus 8 (16%)
Dyslipidemia 18 (38%)
Previous MI 25 (51%)
Family history of premature CAD 18 (39%)
Cigarette smoking within 1 year 17 (35%)
Previous CABG 5 (10%)
Previous PTCA of the target vessel 8 (17%)
Angina class according to CCS
0 5 (10%)
I 6 (12%)
II 6 (12%)
III 12 (25%)
IV 20 (41%)
Vessel treated
LAD 16 (33%)
RCA 21 (43%)
LCx 12 (25%)
Data presented are mean value 6 SD or number (%) of patients. CABG 5
coronary artery bypass graft surgery; CAD 5 coronary artery disease; CCS 5
Canadian Cardiovascular Society; LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex coronary artery; MI 5 myocardial infarction;
PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right coro-
nary artery.
Table 2. Lesion Morphology by Coronary Angiography
Before intervention
AHA/ACC classification
A 3 (6%)
B1 11 (23%)
B2 25 (53%)
C 8 (17%)
Lesion length (mm) 9.6 6 4.0
Angulation (degrees) 36 6 32
Thrombus 3 (6%)
Eccentricity 22 (47%)
TIMI flow
0 0
1 1 (2%)
2 3 (6%)
3 43 (92%)
After intervention
Thrombus 1 (2%)
Dissection $grade B 3 (6%)
TIMI flow
2 1 (2%)
3 46 (98%)
Abrupt closure 0
Distal embolization 0
Perforation 0
Data presented are number (%) of patients or mean value 6 SD. AHA/
ACC 5 American Heart Association/American College of Cardiology; TIMI 5
Thrombolysis in Myocardial Infarction.
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Intravascular ultrasound. Intravascular ultrasound data
were available for 43 patients. Minimal lumen CSA measured
within the stent increased progressively after 8-, 12- and 16-atm
inflations (5.6 6 1.0 to 6.8 6 1.0 to 7.4 6 1.2 mm2, p , 0.001)
(Fig. 2). Percent expansion also increased from 8 to 12 atm
(60 6 16% to 73 6 16%, p , 0.001), but did not increase
further from 12 to 16 atm (73 6 16% to 75 6 17%, p 5 NS),
owing to a concomitant increase in the reference vessel CSA
(9.6 6 2.2 to 10.1 6 2.0 mm2, p , 0.001). When the minimal
lumen CSA within the stent is normalized for the reference
CSA measured before high pressure dilation (to avoid the
confounding increase in reference area), there is a progressive
rightward shift in the cumulative distribution function curves at
12 and 16 atm (Fig. 3). The mean recovery of measured
balloon CSA at 16 atm is ;80% (Fig. 4). The eccentricity ratio
was similar after all three dilation pressures (84 6 4% vs. 84 6
6% vs. 83 6 5%, p 5 NS [8, 12 and 16 atm, respectively]).
Discussion
Randomized trials have consistently demonstrated that the
use of the Palmaz-Schatz coronary stent is associated with a
reduction in angiographic restenosis and the need for subse-
quent revascularization compared with conventional balloon
angioplasty (1,4,5). By favorably addressing the problems of
acute mechanical instability and late restenosis, stents repre-
sent a true breakthrough in interventional cardiology.
Despite the increasingly important role played by stents in
the percutaneous treatment of complex coronary artery dis-
ease, the presently available devices (Palmaz-Schatz and
Gianturco-Roubin) are limited by mechanical problems, in-
cluding excessive rigidity, articulation site defects, nonuniform
expansion and recoil (Gianturco-Roubin). These mechanical
limitations contribute to difficulties in delivering stents through
tortuous vessels and in achieving optimal acute results. A
number of newer “second-generation” stents have thus been
proposed to overcome the limitations of the initial devices and
have recently entered clinical evaluation.
The MultiLink stent. Like the Palmaz-Schatz coronary
stent, the ACS MultiLink stent is constructed by laser etching
of a stainless-steel tube. The unique geometric arrangement of
interposed loops (as opposed to the “stacked” rectangular
pattern of the Palmaz-Schatz coronary stent) improves flexi-
bility in the nonexpanded state, which may facilitate delivery
through tortuous vessels. When open, this design imparts a
high degree of axial and radial strength, rendering the stent
resistant to axial and radial collapse (6). Finally, uniform cell
Figure 2. Angiograms (A) and IVUS images (B) from a representative
patient. Baseline angiography (A) demonstrates a tight stenosis in the
proximal left anterior descending coronary artery (top). A 15-mm
MultiLink stent is positioned across the stenosis (B, middle panel).
After deployment at 8 atm, a residual stenosis remains within the
stented segment (A, third panel). After 16-atm dilation, a smooth
lumen without angiographic narrowing is observed. Intravascular
ultrasound imaging performed during this procedure after 8, 12 and
16 atm (B, left to right) shows progressive increases in lumen CSA
within the stent.
Table 3. Quantitative Coronary Angiography
No. of
Pts
Reference
Vessel
(mm)
Minimal Lumen
Diameter
(mm)
Percent
Stenosis
Before treatment 47 3.18 6 0.49 1.24 6 0.46 61 6 13
After stent placement
(8 atm)
41 3.20 6 0.46 2.49 6 0.42 22 6 11
Final lesion 47 3.23 6 0.45 2.64 6 0.46 18 6 10
Final stent 47 3.23 6 0.45 2.98 6 0.28* 7 6 9†
*p , 0.001 (before treatment vs. after stent vs. final stent minimal lumen
diameter). †p 5 0.001 (before treatment vs. after stent vs. final stent percent
stenosis). Data presented are number of patients (Pts) or mean value 6 SD.
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size and the ability to provide flexibility without a discrete
articulation site (invariably the portion with the smallest CSA
within the Palmaz-Schatz–treated lesion) largely overcome the
problem of plaque prolapse into the lumen.
Although these unique properties of the MultiLink stent
may offer theoretic advantages over earlier designs, direct
comparison cannot be made without a prospective, random-
ized clinical trial. This multicenter pilot study, however, used
quantitative coronary angiography and serial IVUS to address
issues pertaining to clinical safety and the response of the stent
to adjunctive high pressure dilation, before commencement of
the randomized trial.
Figure 3. Cumulative distribution function
curves (after 8, 12 and 16 atm) are shown
for the ratio of the minimal lumen CSA
within the stent to the reference lumen CSA
at 8 atm.
Figure 4. Cumulative distribution function
curves are shown for the ratio of the mini-
mal lumen CSA within the stent to the
nominal balloon CSA (solid squares) and
the measures of balloon CSA (open cir-
cles). QCA 5 quantitative coronary angiog-
raphy.
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Clinical and angiographic outcome. In this study, Mul-
tiLink stents were deployed successfully in all 49 patients
without major adverse clinical events. Because the majority of
lesions were AHA/ACC grade B2 or C and a significant
percentage of lesions (30%) were in angulated segments
(.45°), this excellent deliverability suggests that the MultiLink
stent can be delivered safely and reliably in complex lesion
subsets. The absence of major ischemic complications (partic-
ularly subacute thrombosis) within 30 days of stent placement
supports the thromboresistance of the MultiLink stent ob-
served in earlier animal studies (7), compared with the ex-
pected subacute thrombosis rate (3%) with the Palmaz-Schatz
stent using this anticoagulation regimen (1,8). However, the
small sample size in this study precludes direct comparison of
the rate of uncommon events such as thrombosis with the rate
reported for the Palmaz-Schatz stent. With the planned con-
version to an antiplatelet regimen (aspirin and ticlopidine) in
the randomized trial, acceptably low rates (,1%) of subacute
thrombosis are expected (8). The low incidence (2.0%) of
revascularization of the target site at 12 months is consistent
with the attainment of a large lumen after the procedure and
lack of plaque prolapse through an articulation site. Whether
the performance of the MultiLink stent procedure in these
aspects exceeds that of the Palmaz-Schatz stent cannot be
determined from this pilot registry, but will be addressed
directly in the larger ACS MultiLink Stent Clinical Equiva-
lence in De Novo Lesions Trial (ASCENT) now in progress.
Intravascular ultrasound assessment. Other than demon-
strating the preliminary safety of the MultiLink stent, however,
the primary goal of this pilot trial was to evaluate the proposed
technique for stent deployment. By quantitative angiography,
the residual stenosis after stent deployment at 8 atm was 22%,
but decreased to 7% after adjunctive balloon dilation to
16 atm. These data are similar to those observed after place-
ment of Palmaz-Schatz stents and support the use of routine
high pressure (14 to 16 atm) after dilation to achieve optimal
angiographic results with the MultiLink stent (9). In addition,
the fact that the MultiLink stent lacks a discrete articulation
site may allow for more uniform scaffolding throughout the
length of the stent. In contrast, Ikari et al. (10) demonstrated
that the smallest mean lumen diameter within the Palmaz-
Schatz stent is at the articulation site immediately after de-
ployment. Hoffman et al. (11) confirmed this finding using
serial IVUS. In this cohort without significant lesion calcifica-
tion, the lack of a discrete articulation site may also have
obviated the need for extremely high pressure (.18 atm) after
dilation, as is often used to overcome recoil at the articulation
site within the Palmaz-Schatz stent (11).
The use of serial IVUS allows for more precise quantifica-
tion of variables of stent expansion (12). In the present study,
progressive increases in lumen CSA within the stent are
observed from 8 to 12 to 16 atm. Percent stent expansion
increased significantly from 8 to 12 atm, and to a lesser extent
from 12 to 16 atm, given a concomitant increase in the
reference vessel area at the higher pressures. When the
minimal lumen CSA within the stent is normalized to the
reference lumen CSA at 8 atm (to avoid the confounding issue
of reference vessel enlargement after high pressure dilation),
there is additional gain from 12 to 16 atm. This is reflected by
the progressive rightward shift of the cumulative distribution
function curve from 8 to 12 to 16 atm (Fig. 2).
The criteria proposed for IVUS-guided “optimal stenting”
have become more stringent over the past several years. They
currently include the attainment of a 0.7 ratio of lumen CSA
within the stent to reference lumen CSA (9,12,13). In this
study, however, only 64% of stents achieved a lumen to mean
reference area ratio $0.70. Because the ratio of stent lumen
CSA to measured balloon CSA was ;0.70 (similar to the 0.60
to 0.70 reported by IVUS for the Palmaz-Schatz stent [9]), it
may be necessary to use balloons with an inflated diameter
10% to 20% over the reference lumen diameter to overcome
lumen recoil and to achieve 90% of the reference vessel CSA.
The use of slightly oversized balloons or adjunctive high
pressure (.16 atm) dilation was prohibited by the study
protocol; thus, these traditional strategies used to expand the
stent more fully could not be used. However, the excellent
clinical results of this pilot study (absence of occlusive throm-
bosis and low incidence [2.0%] of target lesion revasculariza-
tion) suggest that the attainment of an arbitrary, IVUS-defined
criterion (such as lumen/reference CSA ratio .0.70) may not
be clinically necessary. Even at current levels of expansion, the
MultiLink stent appears to have a relatively high ratio of the
minor to major axes (eccentricity ratio .0.80), suggesting its
uniform expansion from the collapsed to the deployed state.
Recently, Stone et al. (14) reported similar observations using
serial IVUS in Palmaz-Schatz stents.
Study limitations. The small sample size and narrow inclu-
sion criteria of this pilot study do not permit generalization of
the findings to a much larger population of patients in whom
coronary stents are placed. The lack of routine angiographic
follow-up also precludes any precise quantification of angio-
graphic restenosis or biologic response to injury. Finally, the
absence of a control group treated with approved stents or
other catheter-based modalities does not allow for direct compar-
ison with other devices. Such comparisons must be deferred until
the larger, randomized ASCENT trial is completed.
Conclusions. This pilot study suggests that the ACS Mul-
tiLink stent has favorable characteristics in terms of deform-
ability, expansion of minimal lumen diameter, thromboresistance
on an aspirin/warfarin regimen and freedom from clinically
driven, target-driven revascularization during 6 to 12 months of
follow-up. Final inflation pressures in the 12 to 16 atm range
appear to be adequate to obtain expansion to 7% residual
stenosis by quantitative angiography. Intravascular ultrasound,
however, suggests that use of postdilating balloons with inflated
diameters of 10% to 20% over the reference diameter would be
necessary to achieve a final stent CSA .80% of the reference
lumen. The preliminary data, however, are encouraging for the
completion of the large, randomized ASCENT trial comparing
the ACS MultiLink stent with the approved Palmaz-Schatz stent
in focal disease in native coronary arteries.
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